Tenax Therapeutics Inc (TENX) Actualités

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global...

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites...

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet...

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of...

Tenax Therapeutics to Present at the 36th Annual Roth Conference

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3...

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 8-K - Current report

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals